JohnLoh00 personal page - To The Moon

JohnLoh00

No personal profile

2Follow

1Followers

0Topic

0Badge

2021-09-22

Ok

Sorry, the original content has been removed

2021-09-21

Ok

Got $1,000? Buy These Hot Growth Stocks Before They Take Off

2021-09-20

Ok

Sorry, the original content has been removed

2021-09-18

Ok

Sorry, the original content has been removed

2021-09-16

Ok

Sorry, the original content has been removed

2021-09-16

Ok

Procept BioRobotics spikes 40% on its first day of trading

2021-09-16

Ok

Procept BioRobotics spikes 40% on its first day of trading

2021-09-15

Ok

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3580436163482352","uuid":"3580436163482352","gmtCreate":1617342893541,"gmtModify":1617342893541,"name":"JohnLoh00","pinyin":"johnloh00","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":2,"tweetSize":21,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.81%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":869838777,"gmtCreate":1632271331099,"gmtModify":1676530739361,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869838777","repostId":"2169637141","repostType":4,"isVote":1,"tweetType":1,"viewCount":1541,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860401147,"gmtCreate":1632193476289,"gmtModify":1676530722508,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860401147","repostId":"1159687756","repostType":4,"repost":{"id":"1159687756","kind":"news","pubTimestamp":1632190724,"share":"https://ttm.financial/m/news/1159687756?lang=en_US&edition=fundamental","pubTime":"2021-09-21 10:18","market":"us","language":"en","title":"Got $1,000? Buy These Hot Growth Stocks Before They Take Off","url":"https://stock-news.laohu8.com/highlight/detail?id=1159687756","media":"Motley Fool","summary":"You don't need a lot of money to make a difference with the right growth stocks.","content":"<p><b>Key Points</b></p>\n<ul>\n <li>A little money can go a long way when volatility turns stocks you want to buy into even bigger bargains.</li>\n <li>Crocs is a name on this list, a surprising winner that is still sneaking up on investors with its masterful turnaround.</li>\n <li>The other two names are growing fast in a booming streaming video market.</li>\n</ul>\n<p>The market's off to a shaky start this week, but there's opportunity in the volatility. Now is a good time to size up some of the stocks on your shopping to list, asking yourself if the stories are getting better even as the stocks are going nowhere.</p>\n<p>You don't need a lot of money to take advantage of the ups and downs of Wall Street. Just $1,000 can go a long way if you are buying the right growth stocks, and right now I like&nbsp;<b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>fuboTV</b>(NYSE:FUBO), and&nbsp;<b>Roku</b>(NASDAQ:ROKU). The first one is a surprising winner in 2021. The other two are surprising laggards. Even though $1,000 will buy you just a couple of shares in some of these names, let's get into why I see these as growth stocks that are about to take off.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5eb5fb95534102c76d3a38d3bea8ad5b\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>1. Crocs</b></p>\n<p>If you haven't been following Crocs lately you may be surprised at how well the stock has been doing. The maker of hole-filled resin shoes has more than doubled in 2021, nearly quadrupling since the start of last year.</p>\n<p>Crocs has had its ups and downs over the years, but it's clearly on an upswing now. The revival started in 2017 when a new CEO came in just as the maker of unique footwear was posting its third straight year of declining sales. Revenue growth turned slightly positive in 2018 with a 6% increase, followed by back-to-back years of 13% top-line upticks. This year Crocs is running on an entirely different level.</p>\n<p>Back in February Crocs was targeting 20% to 25% revenue gains for all of 2021, a great achievement as it would be nearly doubling its growth from the prior year. In late April the guidance was bumped to 40% to 50% in top-line growth, and this summer it got boosted again. Crocs now sees a 60% to 65% increase in revenue in 2021.</p>\n<p>The pandemic made us appreciate Crocs again. We chose comfort over fashion during the shelter-in-place phase of the pandemic. Now that we're out and about again we're not giving up our Crocs. We're seeing celebrities strutting in Crocs at media events and out in the wild. Crocs are showing up in movies like this summer's&nbsp;<i>Suicide Squad</i>. The stock may have hit&nbsp;an all-time high last week, but with a lot of people still skeptical on the turnaround the bullish argument here is that the rally is just beginning.</p>\n<p><b>2. fuboTV</b></p>\n<p>When you size up the IPO class of 2020, fuboTV should be the teacher's pet. Some debutantes appear to be peaking just before their stock offerings, but the live TV streaming service is&nbsp;stepping on the gas. Let's just go over the top-line performance in fuboTV's first four quarters as a public company.</p>\n<ul>\n <li>Q3 2020: 71% revenue growth.</li>\n <li>Q4 2020: 98% revenue growth.</li>\n <li>Q1 2021: 135% revenue growth.</li>\n <li>Q2 2021: 196% revenue growth.</li>\n</ul>\n<p>A 138% increase in subscribers over the past year coupled with a 30% pop in average revenue per user is why fuboTV's revenue has nearly tripled. The near-term outlook is even more exciting. As a sports-minded streaming service -- with more than three dozen of its over 100 channels dedicated to live sporting events -- it knows its audience. It introduced free-to-play predictive games and live layered stats this summer, and it expects to roll out a sportsbook to allow viewers to place cash bets on the games they're watching before the end of the year.</p>\n<p>Despite the perpetual improvement at fuboTV the stock is roughly where it was when the year began. With sports season heating up, fuboTV's engaged audience will help it win this game.</p>\n<p><b>3. Roku</b></p>\n<p>There are worse things than standing in place, and right now Roku is trading slightly lower in 2021. It doesn't seem fair. Roku continues to be the platform of choice for folks streaming from home, with 38% of all smart TVs rolling out with Roku's operating system as the default factory-installed operating system. If you don't happen to buy a Roku-ready TV you can buy a dongle for as little as $20 to $30 that will plug into one of your TV's HDMI ports.</p>\n<p>This is a growing market, and even if viewing hours slipped this summer as we began to venture outside again the long-term trend is undeniable. We love streaming video entertainment from home. Sunday's Emmy Awards is another reminder that the best shows on TV these days are largely on premium streaming services.</p>\n<p>Despite the slight dip in sequential consumption in its latest quarter and the&nbsp;recent challenge&nbsp;of a competitor introducing its own TVs, Roku has never been better. The record 55.1 million active accounts on the platform at the end of June was a 28% increase from where it was a year ago, and like fuboTV we're seeing average revenue per user advance at a double-digit percentage clip. Roku is a worthy leader among&nbsp;streaming service stocks. The stock taking a small step back in 2021 at a time when the fundamentals continue to move forward makes this a strong candidate to take off once the dust settles.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These Hot Growth Stocks Before They Take Off</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These Hot Growth Stocks Before They Take Off\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-21 10:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/20/got-1000-buy-these-hot-growth-stocks-before-they-t/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nA little money can go a long way when volatility turns stocks you want to buy into even bigger bargains.\nCrocs is a name on this list, a surprising winner that is still sneaking up on ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/20/got-1000-buy-these-hot-growth-stocks-before-they-t/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CROX":"卡骆驰","ROKU":"Roku Inc","FUBO":"fuboTV Inc."},"source_url":"https://www.fool.com/investing/2021/09/20/got-1000-buy-these-hot-growth-stocks-before-they-t/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159687756","content_text":"Key Points\n\nA little money can go a long way when volatility turns stocks you want to buy into even bigger bargains.\nCrocs is a name on this list, a surprising winner that is still sneaking up on investors with its masterful turnaround.\nThe other two names are growing fast in a booming streaming video market.\n\nThe market's off to a shaky start this week, but there's opportunity in the volatility. Now is a good time to size up some of the stocks on your shopping to list, asking yourself if the stories are getting better even as the stocks are going nowhere.\nYou don't need a lot of money to take advantage of the ups and downs of Wall Street. Just $1,000 can go a long way if you are buying the right growth stocks, and right now I like Crocs (NASDAQ:CROX),fuboTV(NYSE:FUBO), and Roku(NASDAQ:ROKU). The first one is a surprising winner in 2021. The other two are surprising laggards. Even though $1,000 will buy you just a couple of shares in some of these names, let's get into why I see these as growth stocks that are about to take off.\nIMAGE SOURCE: GETTY IMAGES.\n1. Crocs\nIf you haven't been following Crocs lately you may be surprised at how well the stock has been doing. The maker of hole-filled resin shoes has more than doubled in 2021, nearly quadrupling since the start of last year.\nCrocs has had its ups and downs over the years, but it's clearly on an upswing now. The revival started in 2017 when a new CEO came in just as the maker of unique footwear was posting its third straight year of declining sales. Revenue growth turned slightly positive in 2018 with a 6% increase, followed by back-to-back years of 13% top-line upticks. This year Crocs is running on an entirely different level.\nBack in February Crocs was targeting 20% to 25% revenue gains for all of 2021, a great achievement as it would be nearly doubling its growth from the prior year. In late April the guidance was bumped to 40% to 50% in top-line growth, and this summer it got boosted again. Crocs now sees a 60% to 65% increase in revenue in 2021.\nThe pandemic made us appreciate Crocs again. We chose comfort over fashion during the shelter-in-place phase of the pandemic. Now that we're out and about again we're not giving up our Crocs. We're seeing celebrities strutting in Crocs at media events and out in the wild. Crocs are showing up in movies like this summer's Suicide Squad. The stock may have hit an all-time high last week, but with a lot of people still skeptical on the turnaround the bullish argument here is that the rally is just beginning.\n2. fuboTV\nWhen you size up the IPO class of 2020, fuboTV should be the teacher's pet. Some debutantes appear to be peaking just before their stock offerings, but the live TV streaming service is stepping on the gas. Let's just go over the top-line performance in fuboTV's first four quarters as a public company.\n\nQ3 2020: 71% revenue growth.\nQ4 2020: 98% revenue growth.\nQ1 2021: 135% revenue growth.\nQ2 2021: 196% revenue growth.\n\nA 138% increase in subscribers over the past year coupled with a 30% pop in average revenue per user is why fuboTV's revenue has nearly tripled. The near-term outlook is even more exciting. As a sports-minded streaming service -- with more than three dozen of its over 100 channels dedicated to live sporting events -- it knows its audience. It introduced free-to-play predictive games and live layered stats this summer, and it expects to roll out a sportsbook to allow viewers to place cash bets on the games they're watching before the end of the year.\nDespite the perpetual improvement at fuboTV the stock is roughly where it was when the year began. With sports season heating up, fuboTV's engaged audience will help it win this game.\n3. Roku\nThere are worse things than standing in place, and right now Roku is trading slightly lower in 2021. It doesn't seem fair. Roku continues to be the platform of choice for folks streaming from home, with 38% of all smart TVs rolling out with Roku's operating system as the default factory-installed operating system. If you don't happen to buy a Roku-ready TV you can buy a dongle for as little as $20 to $30 that will plug into one of your TV's HDMI ports.\nThis is a growing market, and even if viewing hours slipped this summer as we began to venture outside again the long-term trend is undeniable. We love streaming video entertainment from home. Sunday's Emmy Awards is another reminder that the best shows on TV these days are largely on premium streaming services.\nDespite the slight dip in sequential consumption in its latest quarter and the recent challenge of a competitor introducing its own TVs, Roku has never been better. The record 55.1 million active accounts on the platform at the end of June was a 28% increase from where it was a year ago, and like fuboTV we're seeing average revenue per user advance at a double-digit percentage clip. Roku is a worthy leader among streaming service stocks. The stock taking a small step back in 2021 at a time when the fundamentals continue to move forward makes this a strong candidate to take off once the dust settles.","news_type":1,"symbols_score_info":{"ROKU":0.9,"CROX":0.9,"FUBO":0.9}},"isVote":1,"tweetType":1,"viewCount":2741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860067721,"gmtCreate":1632108948463,"gmtModify":1676530702855,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860067721","repostId":"2168505605","repostType":4,"isVote":1,"tweetType":1,"viewCount":1970,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887097920,"gmtCreate":1631940583860,"gmtModify":1676530675150,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887097920","repostId":"2168574191","repostType":4,"isVote":1,"tweetType":1,"viewCount":1662,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885045807,"gmtCreate":1631748395909,"gmtModify":1676530622670,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885045807","repostId":"1121883775","repostType":4,"isVote":1,"tweetType":1,"viewCount":2058,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885045088,"gmtCreate":1631748377144,"gmtModify":1676530622661,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/885045088","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://ttm.financial/m/news/2167559884?lang=en_US&edition=fundamental","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1,"symbols_score_info":{"PRCT":0.9}},"isVote":1,"tweetType":1,"viewCount":2448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885042243,"gmtCreate":1631748359982,"gmtModify":1676530622638,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885042243","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://ttm.financial/m/news/2167559884?lang=en_US&edition=fundamental","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1,"symbols_score_info":{"PRCT":0.9}},"isVote":1,"tweetType":1,"viewCount":1843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882896308,"gmtCreate":1631671667604,"gmtModify":1676530605216,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882896308","repostId":"1194314814","repostType":4,"isVote":1,"tweetType":1,"viewCount":1939,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":860401147,"gmtCreate":1632193476289,"gmtModify":1676530722508,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860401147","repostId":"1159687756","repostType":4,"repost":{"id":"1159687756","kind":"news","pubTimestamp":1632190724,"share":"https://ttm.financial/m/news/1159687756?lang=en_US&edition=fundamental","pubTime":"2021-09-21 10:18","market":"us","language":"en","title":"Got $1,000? Buy These Hot Growth Stocks Before They Take Off","url":"https://stock-news.laohu8.com/highlight/detail?id=1159687756","media":"Motley Fool","summary":"You don't need a lot of money to make a difference with the right growth stocks.","content":"<p><b>Key Points</b></p>\n<ul>\n <li>A little money can go a long way when volatility turns stocks you want to buy into even bigger bargains.</li>\n <li>Crocs is a name on this list, a surprising winner that is still sneaking up on investors with its masterful turnaround.</li>\n <li>The other two names are growing fast in a booming streaming video market.</li>\n</ul>\n<p>The market's off to a shaky start this week, but there's opportunity in the volatility. Now is a good time to size up some of the stocks on your shopping to list, asking yourself if the stories are getting better even as the stocks are going nowhere.</p>\n<p>You don't need a lot of money to take advantage of the ups and downs of Wall Street. Just $1,000 can go a long way if you are buying the right growth stocks, and right now I like&nbsp;<b>Crocs</b>&nbsp;(NASDAQ:CROX),<b>fuboTV</b>(NYSE:FUBO), and&nbsp;<b>Roku</b>(NASDAQ:ROKU). The first one is a surprising winner in 2021. The other two are surprising laggards. Even though $1,000 will buy you just a couple of shares in some of these names, let's get into why I see these as growth stocks that are about to take off.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5eb5fb95534102c76d3a38d3bea8ad5b\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>1. Crocs</b></p>\n<p>If you haven't been following Crocs lately you may be surprised at how well the stock has been doing. The maker of hole-filled resin shoes has more than doubled in 2021, nearly quadrupling since the start of last year.</p>\n<p>Crocs has had its ups and downs over the years, but it's clearly on an upswing now. The revival started in 2017 when a new CEO came in just as the maker of unique footwear was posting its third straight year of declining sales. Revenue growth turned slightly positive in 2018 with a 6% increase, followed by back-to-back years of 13% top-line upticks. This year Crocs is running on an entirely different level.</p>\n<p>Back in February Crocs was targeting 20% to 25% revenue gains for all of 2021, a great achievement as it would be nearly doubling its growth from the prior year. In late April the guidance was bumped to 40% to 50% in top-line growth, and this summer it got boosted again. Crocs now sees a 60% to 65% increase in revenue in 2021.</p>\n<p>The pandemic made us appreciate Crocs again. We chose comfort over fashion during the shelter-in-place phase of the pandemic. Now that we're out and about again we're not giving up our Crocs. We're seeing celebrities strutting in Crocs at media events and out in the wild. Crocs are showing up in movies like this summer's&nbsp;<i>Suicide Squad</i>. The stock may have hit&nbsp;an all-time high last week, but with a lot of people still skeptical on the turnaround the bullish argument here is that the rally is just beginning.</p>\n<p><b>2. fuboTV</b></p>\n<p>When you size up the IPO class of 2020, fuboTV should be the teacher's pet. Some debutantes appear to be peaking just before their stock offerings, but the live TV streaming service is&nbsp;stepping on the gas. Let's just go over the top-line performance in fuboTV's first four quarters as a public company.</p>\n<ul>\n <li>Q3 2020: 71% revenue growth.</li>\n <li>Q4 2020: 98% revenue growth.</li>\n <li>Q1 2021: 135% revenue growth.</li>\n <li>Q2 2021: 196% revenue growth.</li>\n</ul>\n<p>A 138% increase in subscribers over the past year coupled with a 30% pop in average revenue per user is why fuboTV's revenue has nearly tripled. The near-term outlook is even more exciting. As a sports-minded streaming service -- with more than three dozen of its over 100 channels dedicated to live sporting events -- it knows its audience. It introduced free-to-play predictive games and live layered stats this summer, and it expects to roll out a sportsbook to allow viewers to place cash bets on the games they're watching before the end of the year.</p>\n<p>Despite the perpetual improvement at fuboTV the stock is roughly where it was when the year began. With sports season heating up, fuboTV's engaged audience will help it win this game.</p>\n<p><b>3. Roku</b></p>\n<p>There are worse things than standing in place, and right now Roku is trading slightly lower in 2021. It doesn't seem fair. Roku continues to be the platform of choice for folks streaming from home, with 38% of all smart TVs rolling out with Roku's operating system as the default factory-installed operating system. If you don't happen to buy a Roku-ready TV you can buy a dongle for as little as $20 to $30 that will plug into one of your TV's HDMI ports.</p>\n<p>This is a growing market, and even if viewing hours slipped this summer as we began to venture outside again the long-term trend is undeniable. We love streaming video entertainment from home. Sunday's Emmy Awards is another reminder that the best shows on TV these days are largely on premium streaming services.</p>\n<p>Despite the slight dip in sequential consumption in its latest quarter and the&nbsp;recent challenge&nbsp;of a competitor introducing its own TVs, Roku has never been better. The record 55.1 million active accounts on the platform at the end of June was a 28% increase from where it was a year ago, and like fuboTV we're seeing average revenue per user advance at a double-digit percentage clip. Roku is a worthy leader among&nbsp;streaming service stocks. The stock taking a small step back in 2021 at a time when the fundamentals continue to move forward makes this a strong candidate to take off once the dust settles.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? Buy These Hot Growth Stocks Before They Take Off</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? Buy These Hot Growth Stocks Before They Take Off\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-21 10:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/20/got-1000-buy-these-hot-growth-stocks-before-they-t/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nA little money can go a long way when volatility turns stocks you want to buy into even bigger bargains.\nCrocs is a name on this list, a surprising winner that is still sneaking up on ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/20/got-1000-buy-these-hot-growth-stocks-before-they-t/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CROX":"卡骆驰","ROKU":"Roku Inc","FUBO":"fuboTV Inc."},"source_url":"https://www.fool.com/investing/2021/09/20/got-1000-buy-these-hot-growth-stocks-before-they-t/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159687756","content_text":"Key Points\n\nA little money can go a long way when volatility turns stocks you want to buy into even bigger bargains.\nCrocs is a name on this list, a surprising winner that is still sneaking up on investors with its masterful turnaround.\nThe other two names are growing fast in a booming streaming video market.\n\nThe market's off to a shaky start this week, but there's opportunity in the volatility. Now is a good time to size up some of the stocks on your shopping to list, asking yourself if the stories are getting better even as the stocks are going nowhere.\nYou don't need a lot of money to take advantage of the ups and downs of Wall Street. Just $1,000 can go a long way if you are buying the right growth stocks, and right now I like Crocs (NASDAQ:CROX),fuboTV(NYSE:FUBO), and Roku(NASDAQ:ROKU). The first one is a surprising winner in 2021. The other two are surprising laggards. Even though $1,000 will buy you just a couple of shares in some of these names, let's get into why I see these as growth stocks that are about to take off.\nIMAGE SOURCE: GETTY IMAGES.\n1. Crocs\nIf you haven't been following Crocs lately you may be surprised at how well the stock has been doing. The maker of hole-filled resin shoes has more than doubled in 2021, nearly quadrupling since the start of last year.\nCrocs has had its ups and downs over the years, but it's clearly on an upswing now. The revival started in 2017 when a new CEO came in just as the maker of unique footwear was posting its third straight year of declining sales. Revenue growth turned slightly positive in 2018 with a 6% increase, followed by back-to-back years of 13% top-line upticks. This year Crocs is running on an entirely different level.\nBack in February Crocs was targeting 20% to 25% revenue gains for all of 2021, a great achievement as it would be nearly doubling its growth from the prior year. In late April the guidance was bumped to 40% to 50% in top-line growth, and this summer it got boosted again. Crocs now sees a 60% to 65% increase in revenue in 2021.\nThe pandemic made us appreciate Crocs again. We chose comfort over fashion during the shelter-in-place phase of the pandemic. Now that we're out and about again we're not giving up our Crocs. We're seeing celebrities strutting in Crocs at media events and out in the wild. Crocs are showing up in movies like this summer's Suicide Squad. The stock may have hit an all-time high last week, but with a lot of people still skeptical on the turnaround the bullish argument here is that the rally is just beginning.\n2. fuboTV\nWhen you size up the IPO class of 2020, fuboTV should be the teacher's pet. Some debutantes appear to be peaking just before their stock offerings, but the live TV streaming service is stepping on the gas. Let's just go over the top-line performance in fuboTV's first four quarters as a public company.\n\nQ3 2020: 71% revenue growth.\nQ4 2020: 98% revenue growth.\nQ1 2021: 135% revenue growth.\nQ2 2021: 196% revenue growth.\n\nA 138% increase in subscribers over the past year coupled with a 30% pop in average revenue per user is why fuboTV's revenue has nearly tripled. The near-term outlook is even more exciting. As a sports-minded streaming service -- with more than three dozen of its over 100 channels dedicated to live sporting events -- it knows its audience. It introduced free-to-play predictive games and live layered stats this summer, and it expects to roll out a sportsbook to allow viewers to place cash bets on the games they're watching before the end of the year.\nDespite the perpetual improvement at fuboTV the stock is roughly where it was when the year began. With sports season heating up, fuboTV's engaged audience will help it win this game.\n3. Roku\nThere are worse things than standing in place, and right now Roku is trading slightly lower in 2021. It doesn't seem fair. Roku continues to be the platform of choice for folks streaming from home, with 38% of all smart TVs rolling out with Roku's operating system as the default factory-installed operating system. If you don't happen to buy a Roku-ready TV you can buy a dongle for as little as $20 to $30 that will plug into one of your TV's HDMI ports.\nThis is a growing market, and even if viewing hours slipped this summer as we began to venture outside again the long-term trend is undeniable. We love streaming video entertainment from home. Sunday's Emmy Awards is another reminder that the best shows on TV these days are largely on premium streaming services.\nDespite the slight dip in sequential consumption in its latest quarter and the recent challenge of a competitor introducing its own TVs, Roku has never been better. The record 55.1 million active accounts on the platform at the end of June was a 28% increase from where it was a year ago, and like fuboTV we're seeing average revenue per user advance at a double-digit percentage clip. Roku is a worthy leader among streaming service stocks. The stock taking a small step back in 2021 at a time when the fundamentals continue to move forward makes this a strong candidate to take off once the dust settles.","news_type":1,"symbols_score_info":{"ROKU":0.9,"CROX":0.9,"FUBO":0.9}},"isVote":1,"tweetType":1,"viewCount":2741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860067721,"gmtCreate":1632108948463,"gmtModify":1676530702855,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860067721","repostId":"2168505605","repostType":4,"isVote":1,"tweetType":1,"viewCount":1970,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887097920,"gmtCreate":1631940583860,"gmtModify":1676530675150,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887097920","repostId":"2168574191","repostType":4,"isVote":1,"tweetType":1,"viewCount":1662,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885045088,"gmtCreate":1631748377144,"gmtModify":1676530622661,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/885045088","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://ttm.financial/m/news/2167559884?lang=en_US&edition=fundamental","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1,"symbols_score_info":{"PRCT":0.9}},"isVote":1,"tweetType":1,"viewCount":2448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869838777,"gmtCreate":1632271331099,"gmtModify":1676530739361,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869838777","repostId":"2169637141","repostType":4,"isVote":1,"tweetType":1,"viewCount":1541,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885045807,"gmtCreate":1631748395909,"gmtModify":1676530622670,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885045807","repostId":"1121883775","repostType":4,"isVote":1,"tweetType":1,"viewCount":2058,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882896308,"gmtCreate":1631671667604,"gmtModify":1676530605216,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882896308","repostId":"1194314814","repostType":4,"isVote":1,"tweetType":1,"viewCount":1939,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885042243,"gmtCreate":1631748359982,"gmtModify":1676530622638,"author":{"id":"3580436163482352","authorId":"3580436163482352","name":"JohnLoh00","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3580436163482352","idStr":"3580436163482352"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885042243","repostId":"2167559884","repostType":4,"repost":{"id":"2167559884","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1631721822,"share":"https://ttm.financial/m/news/2167559884?lang=en_US&edition=fundamental","pubTime":"2021-09-16 00:03","market":"us","language":"en","title":"Procept BioRobotics spikes 40% on its first day of trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2167559884","media":"Dow Jones","summary":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go ","content":"<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Procept BioRobotics spikes 40% on its first day of trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProcept BioRobotics spikes 40% on its first day of trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-09-16 00:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Procept BioRobotics spikes 40% on its first day of trading.</p>\n<p><img src=\"https://static.tigerbbs.com/70f6e6c88567a43f408cd96f913f6476\" tg-width=\"1404\" tg-height=\"888\" width=\"100%\" height=\"auto\"></p>\n<p>Procept BioRobotics Corp.&nbsp;is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the <a href=\"https://laohu8.com/S/IPO\">Renaissance IPO ETF</a>&nbsp;has gained 7.4% over the past three months while the S&amp;P 500 has tacked on 4.6%.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p>Customer Acquisition</p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&amp;A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Expenses vs. Revenue</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Percentage</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>144.5%</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>392.3%</p></td>\n  </tr>\n  <tr>\n   <td><p>2019</p></td>\n   <td><p>462.3%</p></td>\n  </tr>\n </tbody>\n</table>\n<p>The Selling, G&amp;A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&amp;A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<table>\n <colgroup></colgroup>\n <tbody>\n  <tr>\n   <td><p><b>Selling, G&amp;A</b></p></td>\n   <td><p><b>Efficiency Rate</b></p></td>\n  </tr>\n  <tr>\n   <td><p>Period</p></td>\n   <td><p>Multiple</p></td>\n  </tr>\n  <tr>\n   <td><p>Six Mos. Ended June 30, 2021</p></td>\n   <td><p>0.6</p></td>\n  </tr>\n  <tr>\n   <td><p>2020</p></td>\n   <td><p>0.1</p></td>\n  </tr>\n </tbody>\n</table>\n<p><b>Market &amp; Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/6fb31b91e96ed681b39c952c72b32105\" tg-width=\"904\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/94b04bc1fd096b33535887c4c77d17a5\" tg-width=\"906\" tg-height=\"442\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/72b3c6e00fbb7d021141642eb8f69104\" tg-width=\"907\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/43410c6bd6487d96c4424db32f9c94e7\" tg-width=\"907\" tg-height=\"438\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/0457da194f7ee652bf4bad3deb6fbf40\" tg-width=\"908\" tg-height=\"441\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/12ac204e8226347ff04eb9ca845142aa\" tg-width=\"902\" tg-height=\"439\" referrerpolicy=\"no-referrer\"></p>\n<p>As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2167559884","content_text":"Procept BioRobotics spikes 40% on its first day of trading.\n\nProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol \"PRCT.\" With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\n\n\n\n\nSelling, G&A\nExpenses vs. Revenue\n\n\nPeriod\nPercentage\n\n\nSix Mos. Ended June 30, 2021\n144.5%\n\n\n2020\n392.3%\n\n\n2019\n462.3%\n\n\n\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\n\n\n\nSelling, G&A\nEfficiency Rate\n\n\nPeriod\nMultiple\n\n\nSix Mos. Ended June 30, 2021\n0.6\n\n\n2020\n0.1\n\n\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\n\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).","news_type":1,"symbols_score_info":{"PRCT":0.9}},"isVote":1,"tweetType":1,"viewCount":1843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}